Recent clinical trial results from a study on heterologous vaccination show that the method is five times more effective in neutralizing antibody levels than a homologous booster.


Incorporated in 2009, CanSinoBIO is committed to the research, production, and commercialization of innovative vaccines for China and global public health security. It possesses five integrated platform technologies including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology, as well as formulation and delivery technology.

As of today, it has established a robust pipeline of 17 vaccines preventing 12 diseases, including the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) conditionally approved in 2021, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) approved in the same year. 

Reuters reported that CanSinoBIO's shot uses a modified common cold virus known as adenovirus to ferry genetic information from the spike protein of the coronavirus into the human body.

CanSinoBIO is committed to providing timely and broad immune protection, making its vaccines more accessible to regions with insufficient storage facilities and medical resources, and reducing the burden placed on healthcare systems and medical workers. Currently, its vaccine Convidecia is approved in more than ten countries, including China, Pakistan, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Indonesia, and Malaysia.

What is a heterologous booster?

Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants.

Recent clinical trial results from a study on heterologous vaccination conducted by the Jiangsu Provincial Center for Disease Control and Prevention showed that after two-dose priming with an inactivated COVID-19 vaccine, a single dose of Convidecia as a heterologous booster could induce neutralizing antibody levels at 14 days post-vaccination and is five times more effective in neutralizing antibody levels than a homologous booster of inactivated vaccine.

According to a recent study jointly published by China's CAS Key Laboratory of Pathogenic Microbiology and Immunology, the Institute of Microbiology of the Chinese Academy of Sciences and others, those who had two doses of inactivated vaccine and then received Convidecia as a heterologous booster 4 – 8 months later were found to have neutralizing antibody levels against the prototype strain that was 7 times higher than those boosted with recombinant protein vaccines.

The study found that for the Omicron variant, Convidecia generates neutralizing antibody levels 6 times and 3 times higher than the groups given inactivated vaccines and recombinant protein vaccines, respectively. In addition, administering Convidecia as a booster can also induce a significant CD8+T cellular immune response, which could rapidly kill virus-infected cells and reduce the chance of severe illness and death, providing both humoral and cellular immunity.

Recent interim guidance for heterologous COVID-19 vaccination from the World Health Organization recommended that for people who have initial administration with inactivated COVID-19 vaccines, they may choose either adenovirus-vectored or mRNA vaccines as the subsequent booster doses. In November 2021, the Ministry of Health of Argentina recommended CanSinoBIO's Convidecia as a booster for people who have received the inactivated vaccines for at least one month, including those aged 50 years old and above.

#THE S MEDIA #Media Milenial